Summary
Abbott Laboratories (ABT) filed an 8-K on October 19, 2022, to report its third-quarter 2022 financial results. The filing primarily consists of a press release detailing these results and is furnished as an exhibit. Investors should note that Abbott utilizes non-GAAP financial measures, which exclude certain items such as acquisition-related expenses, restructuring costs, voluntary recalls, litigation, and impairment charges, among others. The company states that these adjustments provide a clearer view of ongoing business performance, aligning with how management internally assesses results.
Key Highlights
- 1Abbott Laboratories reported its third-quarter 2022 financial results via an 8-K filing on October 19, 2022.
- 2The primary content of the filing is a press release furnished as Exhibit 99.1, detailing the Q3 2022 operational and financial performance.
- 3Abbott utilizes non-GAAP financial measures in its reporting, adjusting for items deemed unusual or unpredictable.
- 4Examples of adjustments in non-GAAP measures include expenses related to acquisitions, restructuring, cost reduction, voluntary recalls, litigation, asset impairments, and tax-related items.
- 5The company believes these non-GAAP measures offer greater visibility into ongoing business performance for investors.
- 6Abbott's management also uses these non-GAAP measures for internal performance monitoring.
- 7Investors are cautioned to consider these non-GAAP measures alongside, not as a substitute for, GAAP financial measures.